Investor Overview

Stock Information
Loading data...

Shares outstanding

82.4 million (as of 8/3/2022)

Press Releases
Oct 11, 2022

Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in...

Oct 6, 2022

Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and...

Oct 3, 2022

Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker...

Sep 23, 2022

-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 -- SAN DIEGO

Sep 19, 2022

Evofem Biosciences (OTCPK: EVFM) is pleased to congratulate University of Illinois Chicago (UIC) Professor Emeritus Donald Waller, Ph.D., on his recognition as Inventor of the Year for his role in...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. 

The Company‘s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at  

The U.S. contraceptive market was estimated at $7.9 billion as of 2021. Every 1% market share of the 42.2 million women in our addressable market represents more than $300 million in net product sales for Evofem.

Evofem intends to expand Phexxi’s global reach and further increase its commercial potential through ex-U.S. licenses. The product is approved in Nigeria, and regulatory dossiers have been submitted in Ghana, Ethiopia and Mexico.

Effective October 3, 2022, the Company's common stock trades on the OTCQB Venture Market under the ticker symbol "EVFM". 

Featured Event
Tuesday, October 25, 2022
11:35 am PDT

"Pregnancies by Acts of Intercourse with Vaginal pH Modulator: Results from the AMPOWER Study," was given as an oral presentation during the ASRM 2022 Scientific Congress.

View All

Latest Financial Results

Q2 2022, Ended June 30th, 2022

Earnings Release
Earnings Call
10-Q Filing